Celeritas v. Rockwell: The NDA That Outlived an Invalid Patent

Litigants sometimes treat a non-disclosure agreement as a lesser cousin of patent and trade-secret rights, useful but redundant. Celeritas Technologies, Ltd. v. Rockwell International Corp., 150 F.3d 1354 (Fed. Cir. 1998), decided July 20, 1998, shows why that instinct is wrong. The United States Court of Appeals for the Federal Circuit invalidated Celeritas’s patent as anticipated and yet affirmed a $57,658,000 verdict against Rockwell for breaching the parties’ NDA. The contract claim, resting on Rockwell’s own promise, survived the collapse of the patent theory and delivered the entire recovery.

The decision is a foundational lesson in contract-based secrecy protection: a well-drafted NDA can outperform both patent and trade-secret theories on the same facts, because it binds the promisor to its word regardless of whether the information is patentable or ever becomes public. For any company that shares proprietary technology in the course of licensing talks, Celeritas is the case that explains why the paper matters.

At a glance

• Case: Celeritas Technologies, Ltd. v. Rockwell International Corp., 150 F.3d 1354 (Fed. Cir. 1998).
• Decided: July 20, 1998; opinion affirming in part and reversing in part a Central District of California judgment.
• Holding: An NDA is enforced according to its terms; breach liability stands even though the related patent is invalid as anticipated, and Celeritas’s $57,658,000 contract award survives.
• Status: Final; contract verdict affirmed, patent claims held invalid, no double recovery permitted.

The doctrinal frame: three theories, one set of facts

Celeritas pursued three overlapping theories against Rockwell: patent infringement, trade-secret misappropriation, and breach of the NDA. The theories share a factual core but rest on different legal foundations. Patent rights depend on the validity of the claims, which in turn requires novelty under 35 U.S.C. § 102; a single prior-art reference disclosing every claim limitation anticipates and invalidates. Trade-secret protection depends on the information remaining secret and being taken by improper means. But a contract right depends on nothing more than the promise itself. When a party agrees not to use or disclose information except for a defined purpose, the enforceability of that promise turns on contract law, not on whether the information qualifies for patent or trade-secret protection.

That divergence is the engine of the case. The same technology that failed the novelty test for patenting, and might have failed the secrecy test for trade-secret protection once a competitor’s product appeared, was still the subject of an enforceable contractual promise that Rockwell had made and broken.

The facts and posture

In 1993, Michael Dolan, working with Celeritas, developed a signal de-emphasis technique that increased data-transmission rates over analog cellular networks by de-emphasizing the data signal before it entered the cellular channel. Celeritas met with Rockwell, a major modem-chipset maker, to demonstrate the proprietary technology for possible incorporation into Rockwell’s products. The parties signed an NDA under which Rockwell agreed not to disclose or use Celeritas’s proprietary information except to evaluate a potential business arrangement.

The relationship soured. In March 1994, Rockwell told Celeritas it would not license the technology and concurrently launched an internal project to build de-emphasis into its own chipsets. Tellingly, Rockwell assigned the very engineers who had learned the technique under the NDA to the development effort rather than having independent engineers design around it. Celeritas sued. A jury found that Rockwell willfully infringed the patent, misappropriated trade secrets, and breached the NDA, awarding $57,658,000 on each of the patent and contract claims and $26,850,000 in compensatory plus $26,850,000 in exemplary damages on the trade-secret claim. Because Celeritas had stipulated to recover only on the highest single award, the overlapping verdicts did not stack.

The Federal Circuit’s reasoning

The panel decided two of the three theories and never reached the third. On the patent, it reversed. A prior-art reference, the Telebit article, disclosed each limitation of the asserted claims, so the claims were anticipated and invalid as a matter of law. That ruling wiped out the patent recovery.

On the contract, the court affirmed. Substantial evidence supported the jury’s finding that Rockwell breached the NDA. Rockwell argued that the de-emphasis technology had entered the public domain through a competitor’s AT&T Paradyne modem, extinguishing any duty. The court disagreed on the facts: the technology was not readily ascertainable from the marketed modem without specialized equipment and analysis, so it had not become public in a way that discharged Rockwell’s contractual obligation at the time of the breach. Crucially, the court treated the NDA as an independent source of liability. The promise not to use Celeritas’s information except for evaluation was enforceable on its own terms, and Rockwell’s decision to route the disclosed know-how into its own product violated that promise regardless of the patent’s fate.

On damages and double recovery, the stipulation had already done its work below. The district court concluded that the patent award erroneously included a royalty on post-judgment sales; the parties agreed to a remittitur reducing it to $17,484,160, which the willfulness finding doubled to $34,968,320. That left the $57,658,000 contract verdict as the highest of the three theories, so the district court entered judgment on the contract claim alone, together with $85,820.05 in costs and $900,000 in attorney fees. When the Federal Circuit then wiped out the patent, the operative judgment was untouched, because it had never rested on the patent. The trade-secret verdict was never folded into the judgment either, and the court expressly declined to reach Rockwell’s challenges to it: “Because we affirm the determination of liability under the contract claim, we also need not consider Rockwell’s arguments regarding the jury’s verdict for misappropriation of trade secrets.”

What it changed

Celeritas is the canonical demonstration that contract can be the strongest of overlapping IP theories. Patents can be invalidated; trade secrets can be lost to public disclosure; but a contractual promise, enforced by its terms, can carry a case to full recovery even when the other theories fail. The decision teaches transactional lawyers to treat the NDA as a primary protective instrument, not a throwaway, and to draft its use and non-use restrictions, its defined purpose, and its survival provisions with the same care they would give a patent claim.

The case also illustrates a subtle litigation dynamic. By securing full verdicts on multiple theories and stipulating to recover on the highest, Celeritas insulated its recovery from the loss of any single theory. The contract award was already carrying the judgment by the time the appeal was decided, so the patent reversal cost Celeritas nothing. That structure is a template for plaintiffs asserting overlapping rights against a single course of conduct.

Open questions

The opinion does not resolve every question about how long an NDA duty endures after information becomes public. The court found the technology had not entered the public domain at the relevant time, but it did not announce a general rule for when subsequent public disclosure discharges a contractual non-use obligation; that turns on the agreement’s terms and its survival language. Nor did the court address how its reasoning interacts with federal patent policy arguments that contracts should not be used to protect what patent law has placed in the public domain, a tension later cases continue to probe. And because the recovery rested on a stipulation to a single highest award, the opinion offers limited guidance on how overlapping verdicts should be reconciled absent such a stipulation.

Implications for inventors and businesses

• Draft the NDA as a primary shield. Its use and non-use restrictions are enforceable on their own terms, independent of whether the technology is patentable or stays secret. Give the defined purpose and survival clauses real attention.
• Contract can survive when patents and secrets do not. Plaintiffs asserting overlapping theories should preserve a contract claim, because it can carry full recovery after a patent is invalidated or secrecy is lost.
• Structure recovery to withstand a lost theory. Seeking parallel verdicts and electing the highest single award can insulate the recovery if one theory falls on appeal.
• Wall off engineers who receive disclosures. Rockwell’s assignment of the same engineers who saw the technology under the NDA was powerful evidence of breach. Use clean teams to show independent development.

Frequently asked questions

Can a company be liable for breaching an NDA even if the technology was not patentable? Yes. In Celeritas the Federal Circuit affirmed a breach-of-contract verdict against Rockwell even after holding the related patent invalid as anticipated. A non-disclosure agreement is enforced according to its own terms, independent of whether the disclosed technology is patentable or remains secret.

Does an NDA obligation end when the confidential information becomes public? Not automatically. The court found the de-emphasis technology had not entered the public domain when Rockwell breached, because it was not readily ascertainable without specialized equipment. Whether disclosure ends the duty depends on the NDA’s terms and the timing of the alleged breach, not on a general rule.

How could Celeritas recover $57.6 million on contract while losing on the patent? The jury returned a $57,658,000 verdict on the contract claim as well as the patent claim, and Celeritas had stipulated to accept only the highest single award. After the district court remitted the patent award and doubled it for willfulness to $34,968,320, the contract verdict was the highest, so judgment was entered on the contract claim alone. Invalidating the patent therefore took nothing away from the recovery.

Authorities and sources

• Celeritas Technologies, Ltd. v. Rockwell International Corp., 150 F.3d 1354 (Fed. Cir. 1998), opinion (FindLaw): https://caselaw.findlaw.com/court/us-federal-circuit/1152607.html
• U.S. Patent No. 5,386,590 (Dolan), “Apparatus and method for increasing data transmission rate over wireless communication systems using spectral shaping,” the patent held anticipated: https://patents.google.com/patent/US5386590A/en
• 35 U.S.C. § 102 (novelty and anticipation): https://www.law.cornell.edu/uscode/text/35/102
• Quimbee, “Celeritas Technologies v. Rockwell International case brief”: https://www.quimbee.com/cases/celeritas-technologies-v-rockwell-international